Business Of Biotech

We love to hear from our listeners. Send us a message. [https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms] On this week's episode, Milan Kalawadia, CEO, North America, Dr. Reddy's Laboratories, and Arun Swaminathan, Ph.D., CEO, Coya Therapeutics discuss their unique partnership to develop COYA 302, a novel dual-mechanism immunotherapy for the treatment of ALS. The partnership pairs Coya's scientific expertise with Dr. Reddy's manufacturing and commercialization capabilities, putting Coya in a financial position to advance development activities and commercialize COYA 302 upon FDA approval, and providing Dr. Reddy's -- a generics, biosimilars, API, and OTC manufacturer -- with an opportunity to pivot into innovative branded products. Kalawadia and Swaminathan discuss their pathways to the CEO role at each company, respectively, how the partnership came together, ongoing FDA engagement, and what COYA 302 could mean for patients with ALS.  Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech [https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl] tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter [https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/]. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/ [https://www.linkedin.com/in/bencomer/]

We love to hear from our listeners. Send us a message. [https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms] On this week's episode, Bill Holodnak, Cofounder and CEO of Occam Global, a life sciences executive recruitment firm (and occasional investor), shares insights from his decades of experience pairing executives with drug development companies, and talks about the psychology of successful biotech leadership. From building an advisory board to the sequencing of executive hires, such as CSOs, CMOs, CBOs, and CFOs, as a company grows, Holodnak offers specific tips to help founders and investors create leadership teams capable of winning the "slow motion roulette" business of biotech.    Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech [https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl] tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter [https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/]. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/ [https://www.linkedin.com/in/bencomer/]

We love to hear from our listeners. Send us a message. [https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms] On this week's episode, Oury Chetboun, co-founder and CEO of Seekyo, a French biotech, talks about the range of experiences that prepared him to lead a company focused on developing innovative solid tumor treatments that target functional proteins in the tumor micro-environment. Chetboun talks about raising money for preclinical research and navigating the valley of death between research and clinical development, accessing French innovation funding and angel networks, how click chemistry can produce therapies at a lower cost compared to antibody-drug conjugates (ADCs), and the potential use of drug combinations and umbrella trials for testing multiple cancer indications. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech [https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl] tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter [https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/]. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/ [https://www.linkedin.com/in/bencomer/]

We love to hear from our listeners. Send us a message. [https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms] On this week's episode, Ebrahim Delpassand, M.D., founder, CEO, and chairman of the board at RadioMedix talks about his personal journey standing up and growing  a radiopharmaceutical company focused on oncology. Dr. Delpassand discusses the current trends in radiopharmaceutical drug development, the differences between alpha- and beta-emitting isotopes, overcoming manufacturing and supply chain challenges and restraints, and building strategic partnerships with companies like Curium, Fusion (now part of AstraZeneca), and Sanofi. He also offers specific advice to physician-entrepreneurs interested in building their own drug development companies.  Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech [https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl] tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter [https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/]. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/ [https://www.linkedin.com/in/bencomer/]

We love to hear from our listeners. Send us a message. [https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms] On this week's episode, Dr. Hernan Bazan, M.D., co-founder and CEO at New Orleans-based South Rampart Pharma, talks about building an ultra-lean drug development company to address an unmet need observed in his own patients as a surgeon: safe treatments for acute pain. Dr. Bazan explains his strategy for building value through small raises and no full-time salaried employees, co-founding the company with his father -- a scientist and director of the Neuroscience Center of Excellence at Louisiana State University Health Sciences Center -- and why the future of pain management will likely involve multimodal approached personalized to individual patients.  This episode of the Business of Biotech is brought to you by Ecolab.  Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech [https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl] tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter [https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/]. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/ [https://www.linkedin.com/in/bencomer/]